<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01056731</url>
  </required_header>
  <id_info>
    <org_study_id>CSPP100AVE01</org_study_id>
    <nct_id>NCT01056731</nct_id>
  </id_info>
  <brief_title>A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.</brief_title>
  <acronym>ANDROMEDA</acronym>
  <official_title>A 16-week, Prospective, Open Label, Multicenter Study to Evaluate the Effectiveness and Safety of Rasilez® (Aliskiren) Monotherapy or in Addition With Hydrochlorothiazide 12.5 mg or 25 mg in Patients With Hypertension Stage I and II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, not controlled, sequential, dose escalation study of 16 weeks'
      duration. The study is composed of two periods: a 0-2 week optional wash-out period depending
      on previous antihypertensive treatment(s), followed by a 16-week open-label active treatment
      period. Patients will be evaluated every 4 weeks during period 2. Treatment will start with
      Aliskiren 150 mg with dose titration to Aliskiren 300 mg, and addition of HCTZ 12,5 mg and 25
      if control of BP is not achieved (&lt; 140/90 mmHg or 130/ 80 mmHg in diabetics patients). All
      patients who have reached their BP target will be considered as having met the primary
      endpoint and this visit will be considered as the final visit.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients in whom BP control was achieved at the study end point</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients in whom BP control was reached before the addition of HCTZ (ie, at the pre-HCTZ end point</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving overall BP, DBP, an SBP control rate at week 4, 8, 12 and 16.</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in msSPA and msDBP from baseline to different time points</measure>
    <time_frame>4,8,12 and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Aliskiren therapy at different time points</measure>
    <time_frame>4,8,12 and 16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">253</enrollment>
  <condition>High Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Aliskiren and Aliskiren_HCTZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aliskiren 150 mg and 300 mg Hydrochlorothiazide 12.5 mg 25 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren and HCTZ</intervention_name>
    <description>Aliskiren 150 mg and 300 mg Hydrochlorothiazide 12.5 mg and 25 mg</description>
    <arm_group_label>Aliskiren and Aliskiren_HCTZ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients, with essential hypertension, stage I-II, naïve or not controlled with
             monotherapy.

        Exclusion Criteria:

          -  BP&gt; 180/110 mmHg

          -  Pregnant or nursing women

          -  Hypertensive encephalopathy or cerebrovascular accident, transient ischemic - cerebral
             attack, myocardial infarction, unstable angina, coronary bypass surgery, percutaneous
             coronary intervention within 6 month

          -  K &lt;3.5 mEq/L or ≥ 5 mEq/L

          -  Renal impairment

          -  Hypersensitivity to HCTZ or Aliskiren or angioedema due to ACE-I or ARB

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Bolíva</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Carabobo</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Caracas</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Edo Zulia</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Estado Monagas</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Falcón</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Maracaibo Estado Zulia</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Venezuela</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=7304</url>
    <description>Results for CSPP100AVE01 from the Novartis Clinical Trials website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2010</study_first_submitted>
  <study_first_submitted_qc>January 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2010</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high blood pressure</keyword>
  <keyword>aliskiren</keyword>
  <keyword>hydrochlorothiazide</keyword>
  <keyword>control rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

